Boots courts +£11bn in UK high-street care race
This article was originally published in Clinica
The final outcome of the race between US consortium Kohlberg Kravis Roberts (KKR) and Terra Firma to buy UK pharmacy, healthcare services and beauty group Alliance Boots could have implications for the wider UK independent healthcare sector. Today, the KKR-led company AB Acquisitions raised its offer for Boots, valuing it at £11.1bn ($22.2bn), trumping an "indicative proposal" from UK-based private equity group Terra Firma, worth £10.8bn.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.